NCT07177859View on ClinicalTrials.gov

A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Paroxysmal Nocturnal Hemoglobinuria
Interventions
DRUG

NTQ5082 capsules 200 mg

NTQ5082 capsules 200 mg

DRUG

Eculizumab Injection

Eculizumab

Trial Locations (1)

300020

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

Sponsors
All Listed Sponsors
lead

Nanjing Chia-tai Tianqing Pharmaceutical

INDUSTRY